Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13054036 | 1.00 | OPRL1 (0.43) | OPRL1FAAHTDP1POLB | |
| SCHEMBL7562309 | 1.00 | OPRL1 (0.43) | OPRL1FAAHTDP1POLB | |
| SCHEMBL21530786 | 0.99 | FAAH (0.43) | OPRL1FAAHTDP1POLB | |
| SCHEMBL20242350 | 0.99 | FAAH (0.43) | OPRL1FAAHTDP1POLB | |
| SCHEMBL20241591 | 0.94 | FAAH (0.39) | OPRL1FAAHTDP1 | |
| SCHEMBL21528393 | 0.94 | FAAH (0.39) | OPRL1FAAHTDP1 | |
| SCHEMBL21528433 | 0.91 | HDAC8 (0.41) | OPRL1FAAH | |
| SCHEMBL20241410 | 0.91 | HDAC8 (0.41) | OPRL1FAAH | |
| SCHEMBL20242089 | 0.90 | FAAH (0.41) | FAAHTDP1 | |
| SCHEMBL20241402 | 0.90 | FAAH (0.41) | FAAHTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3551192-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2019-10-16 | — | — | EP | claimed |
| WO-2018106519-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-06-14 | — | — | WO | claimed |
| US-10696639-B2 | Heterocyclic compounds as HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696639-B2 | Heterocyclic compounds as HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190337902-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-11-07 | — | — | US | disclosed |
| US-20190337902-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-11-07 | — | — | US | disclosed |
| EP-3551192-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2019-10-16 | — | — | EP | disclosed |
| WO-2018106519-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106519-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20120276118-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | PHARMACOPEIA INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
| US-20080200445-A1 | Use in treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, inhibitors of Human Immunodeficiency Virus, plasmepsins, cathepsin D and protozoal enzymes; 4-imidazolidinone, 5-(3'-chloro[1,1'-biphenyl]-3-yl)-5-cyclopropyl-2-imino-3-(2,2,2-trifluoroethyl)-, for example | SCHERING CORPORATION & PHARMACOPEIA DRUG DISCOVERY, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200445-A1 | Use in treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, inhibitors of Human Immunodeficiency Virus, plasmepsins, cathepsin D and protozoal enzymes; 4-imidazolidinone, 5-(3'-chloro[1,1'-biphenyl]-3-yl)-5-cyclopropyl-2-imino-3-(2,2,2-trifluoroethyl)-, for example | SCHERING CORPORATION & PHARMACOPEIA DRUG DISCOVERY, INC. | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | OPRL1 816/4885FAAH 3473/4885TDP1 534/4885 |
| US-10696639-B2 | Heterocyclic compounds as HIV protease inhibitors | PREP, SERPINB1, PEPD | OPRL1 3661/4885FAAH 629/4885TDP1 1834/4885 |
| US-20190337902-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | PREP, SERPINB1, PEPD | OPRL1 3661/4885FAAH 629/4885TDP1 1834/4885 |
| US-20120276118-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | BACE1, PRSS1, TMPRSS11D | OPRL1 2850/4885FAAH 1334/4885TDP1 168/4885 |
| US-20080200445-A1 | Use in treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, inhibitors of Human Immunodeficiency Virus, plasmepsins, cathepsin D and protozoal enzymes; 4-imidazolidinone, 5-(3'-chloro[1,1'-biphenyl]-3-yl)-5-cyclopropyl-2-imino-3-(2,2,2-trifluoroethyl)-, for example | CTSZ, CTSL, PRSS1 | OPRL1 1670/4885FAAH 3507/4885TDP1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.